CAJ | 학술논문

目的：：检测放疗前后Survivin、P53、Bcl-2和Bax在喉黏膜上皮组织中的表达，探讨其表达及与喉癌放疗敏感性的关系。方法：采用免疫组化SP法检测Survivin、P53、Bcl-2和Bax在56例单纯放疗的喉癌患者石蜡标本中的表达，同时用声带息肉正常喉黏膜组织石蜡块各10例进行对照，对所有患者进行1~5年的随访，同时检测放疗1年、3年、5年后上述四种癌基因蛋白表达情况与初次检测结果进行统计学分析。结果：Survivin、P53和Bcl-2在声带息肉组织中低表达，而Bax则呈相对高表达；Survivin、P53、Bcl-2在喉癌组织中呈高表达，而Bax则呈相对低表达。56例单纯放疗的喉癌患者中，放疗前及放疗1年、3年、5年后Survivin检出率分别是82.1%、67.1%、53.9%、32.8%。分析具有统计学意义(P<0.05)。P53放疗前的表达率76.7%，放疗1年、3年、5年后分别是54.6%、40.1%、26.8%，分析有统计学意义(P<0.05)。 Bcl-2放疗前为80.1%，放疗1年、3年、5年后分别为65.3%、42.1%、30.9%。分析有统计学意义(P<0.05)。 Bax放疗前52.4%，放疗1年、3年、5年后分别是49.3%、50.4%、47.7%，分析无统计学意义(P>0.05)。结论：Survivin、P53和Bcl-2在喉癌组组织中具有高表达，对放疗敏感的喉癌患者放疗后凋亡抑制基因Survivin、P53和Bcl-2呈现表达率降低的趋势，而Bax呈现表达率升高的趋势，将Survivin、P53、Bcl-2和Bax基因作为判断喉癌患者放疗敏感性的分子指标具有一定的临床运用价值。
목적：：검측방료전후Survivin、P53、Bcl-2화Bax재후점막상피조직중적표체，탐토기표체급여후암방료민감성적관계。방법：채용면역조화SP법검측Survivin、P53、Bcl-2화Bax재56례단순방료적후암환자석사표본중적표체，동시용성대식육정상후점막조직석사괴각10례진행대조，대소유환자진행1~5년적수방，동시검측방료1년、3년、5년후상술사충암기인단백표체정황여초차검측결과진행통계학분석。결과：Survivin、P53화Bcl-2재성대식육조직중저표체，이Bax칙정상대고표체；Survivin、P53、Bcl-2재후암조직중정고표체，이Bax칙정상대저표체。56례단순방료적후암환자중，방료전급방료1년、3년、5년후Survivin검출솔분별시82.1%、67.1%、53.9%、32.8%。분석구유통계학의의(P<0.05)。P53방료전적표체솔76.7%，방료1년、3년、5년후분별시54.6%、40.1%、26.8%，분석유통계학의의(P<0.05)。 Bcl-2방료전위80.1%，방료1년、3년、5년후분별위65.3%、42.1%、30.9%。분석유통계학의의(P<0.05)。 Bax방료전52.4%，방료1년、3년、5년후분별시49.3%、50.4%、47.7%，분석무통계학의의(P>0.05)。결론：Survivin、P53화Bcl-2재후암조조직중구유고표체，대방료민감적후암환자방료후조망억제기인Survivin、P53화Bcl-2정현표체솔강저적추세，이Bax정현표체솔승고적추세，장Survivin、P53、Bcl-2화Bax기인작위판단후암환자방료민감성적분자지표구유일정적림상운용개치。
Objective:To investigate the expression of Survivin,P53,Bax and Bcl-2 in laryngeal epithelium, and to investigate the relationship between the expression of laryngeal epithelium and the sensitivity to radiotherapy. Methods: The expression of Survivin group,P53,Bcl-2 and Bax expression were detected in 56 cases of laryngeal cancer patients with radiotherapy paraffin specimens, and laryngeal precancerous lesions such as paraffin blocks of leukoplakia of the larynx and vocal cord polyp of normal laryngeal mucosa in 10 cases were compared, combined with the clinical data, 1-5 year follow-up of all patients, the recurrence cases again the inspection organization, and detection of the four oncogene protein expression and initial test results and survival analysis was performed. Results:Survivin、P53、Bcl-2 showed low expression in vocal cord polyps, however,Bax showed a relatively high expression. Survivin, P53, Bcl-2 had a high expression in laryngeal carcinoma tissues, while Bax showed relatively low expression Of the 56 patients.Before radiotherapy,the rate is 82.1% ,one year after the radiotherapy,three years and five years later , the detection rate of Survivin in laryngeal carcinoma tissues was 67.1%,53.9% and 32.8%,respectively.Statistically significant difference (P < 0.05). The expression rate of P53 before radiotherapy is 76.7%, which is reduced to 54.6% after 1 year, 40.1% after 3 years,and 26.8% 5 years later which were significantly different (P < 0.05). Bcl-2 before radiotherapy was80.1%, after radiotherapy is 65.3%, 42.1%, 30.9%. Bax before radiotherapy is 52.4%,after radiotherapy it was respectively 49.3%, 50.4%, 47.7%, and there was no significant difference (P> 0.05). The expression of Survivin, P53, and Bcl-2 was positively correlated with the expression of Bax negatively. The positive cell rates of the expression of the four genes were correlated with the sensitivity of radiotherapy. Conclusion: the expression of Survivin, P53 and Bcl-2 in laryngeal cancer tissues with high expression, is sensitive to radiotherapy for laryngeal carcinoma patients with radiotherapy after inhibitor gene of apoptosis, Survivin, P53 and Bcl-2 showed the trend to reduce the rate of expression and Bax showed expression rates are on the rise trend, Survivin, P53, Bcl-2 and Bax gene as to judge the sensitivity of radiotherapy in patients with laryngeal cancer molecular marker has certain clinical application value.